LONDON (Reuters) – AstraZeneca may have sufficient of its candidate vaccine for 200 million doses by the tip of 2020, with drug substance for 700 million doses by the tip of the primary quarter of 2021 globally, operations govt Pam Cheng mentioned on Monday.
Cheng instructed a briefing that the corporate would preserve the “active” drug substance in stock whereas it awaited regulatory approval around the globe.
She mentioned there can be sufficient vaccine for 20 million doses in Britain by the tip of the 12 months, with sufficient “active” drug substance for 70 million doses for the UK by the tip of Q1 2021.
She mentioned she anticipated that to translate into four million completed vaccine doses by the tip of 2020, and 40 million completed doses by the tip of Q1 subsequent 12 months.
These calculations had been primarily based on utilizing two full doses, she mentioned, though trial information suggests greater efficacy when the preliminary shot is a half dose.
“If we go with a half dose you can imagine for the initial dose, we will be able to double the number of vaccinations here,” she mentioned.
She mentioned the figures referred to the vaccine doses being manufactured by AstraZeneca, and never these being made by manufacturing companions.
Reporting by Man Faulconbridge and Kate Holton, writing by Alistair Smout; modifying by Catherine Evans and Jason Neely